Is Kava an Opioid? What the Science Actually Shows

Kava is not an opioid. It does not bind to opioid receptors, it is not chemically related to morphine or its derivatives, and when researchers block opioid receptors with naloxone, kava’s pain-relieving effects persist completely unaffected. The confusion tends to arise because kava produces relaxation, mild euphoria, and pain relief that can superficially resemble what opioids do, and because some products sold as “kava” have turned out to contain unlabeled opioid-active substances. The pharmacology of actual kava, though, is a different story entirely.

How Kava Works in the Brain

Kava’s active compounds are called kavalactones, a family of about six major molecules found in the root of the Piper methysticum plant. Rather than targeting a single receptor system the way opioids lock onto mu-opioid receptors, kavalactones appear to work across several brain systems at once. This multi-target pharmacology is part of what makes kava hard to categorize and easy to misunderstand.

The most studied mechanism involves GABA receptors, the same system that benzodiazepines like Valium act on. Kavain, the most abundant kavalactone, directly enhances the activity of GABA-A receptors, increasing the brain’s main inhibitory signaling. Research has shown kavain potentiates these receptors regardless of their subunit makeup, though with stronger effects on certain receptor subtypes found outside the synapse.

1PubMed Central. Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism

Kavalactones also block sodium and calcium ion channels, which can reduce nerve excitability and lower blood pressure.

2PubMed. Anesthetic considerations of the herbal, kava

On top of that, multiple kavalactones inhibit monoamine oxidase B (MAO-B), an enzyme that breaks down dopamine. Yangonin is the most potent of these, and desmethoxyyangonin and methysticin also show strong MAO-B inhibition.

3PubMed. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava)

By slowing dopamine breakdown, kava could boost dopamine levels in areas of the brain involved in mood and motivation, which might explain the subtle euphoria and sociability people report from drinking it.

Yangonin also binds to the CB1 cannabinoid receptor, the same receptor that THC targets. This interaction is selective for CB1 over CB2, suggesting the endocannabinoid system plays a role in kava’s overall psychoactive profile.

4PubMed. Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB₁ receptor ligand

So kava touches GABA, dopamine, endocannabinoid, and ion channel systems simultaneously. None of these are the opioid system. The pharmacological profile is genuinely unusual and doesn’t map neatly onto any single drug class, which is probably why it keeps getting compared to things it isn’t.

The Naloxone Test

If kava worked through opioid receptors, there is a straightforward way to prove it: give an animal naloxone, the opioid-blocking drug used to reverse overdoses, and see if it cancels kava’s effects. Researchers did exactly this in a study using mice. Naloxone completely blocked morphine’s pain-relieving activity, as expected. But it had zero effect on the pain relief produced by kava extracts. The researchers concluded that kava’s analgesic action occurs through entirely non-opioid pathways.

5PubMed. The antinociceptive actions of kava components in mice

This is about as clean a result as pharmacology gets. If kava were activating opioid receptors even partially, naloxone would have weakened its pain relief to some degree. It didn’t. The pain-relief mechanism appears to come from the GABA enhancement, ion channel blockade, and possibly the CB1 receptor activity described above, working in combination rather than through the opioid pathway.

Why Kava Gets Lumped in With Opioids

The confusion has several sources. At the surface level, the subjective experience of drinking kava overlaps with what some people associate with opioids: muscle relaxation, reduced anxiety, pain relief, and a warm sense of calm. Kava bars, which have spread across the United States and Australia in recent years, sometimes market kava alongside kratom, a plant whose primary alkaloid mitragynine does act on opioid receptors. Seeing both products in the same establishment or on the same menu creates a guilt-by-association effect.

But the more concrete problem is product adulteration. A toxicology analysis found that some products labeled and sold as “kava” actually contained kratom alkaloids. One product had both mitragynine and kavalactones; another contained mitragynine with no detectable kavalactones at all, meaning it was essentially a kratom product in kava packaging.

6PubMed. Unlabeled kratom alkaloids detected in products marketed as kava

A case report documented a patient who developed opioid-like withdrawal symptoms after using a product marketed as kava. Testing of that product confirmed it contained kratom derivatives as well as alkaloids from akuamma, another plant with mu-opioid receptor activity. The patient’s withdrawal responded to buprenorphine, a medication specifically for opioid dependence, confirming that the withdrawal was opioid-mediated rather than kava-mediated.

7Journal of Addiction Medicine. When “Kava” Isn’t Kava: Opioid-like Withdrawal Responsive to Buprenorphine: A Case Study

These cases matter because when someone drinks a “kava” product that secretly contains kratom and then develops dependence or withdrawal, the blame falls on kava in casual conversation and sometimes even in clinical settings. The distinction between the labeled product and its actual contents gets lost, and kava’s reputation absorbs the damage.

Does Kava Cause Dependence?

Genuine kava dependence appears to be uncommon, though not impossible. A study that assessed past-year kava users against standard diagnostic criteria found that about 7.5% met criteria for a kava use disorder, and the most common symptoms were using more than intended or for longer than planned, followed by cravings and unsuccessful quit attempts.

8PubMed Central. Clinically characterizing adults who use kava or kratom: Substance use disorder assessment challenges for increasingly popular botanical products

Among those who did meet the criteria for severe kava use disorder, both also used kratom, which makes it difficult to isolate kava’s contribution.

Withdrawal from heavy kava use has been documented, including at least one case severe enough to require hospitalization and treatment with phenobarbital.

9PubMed. Severe kava withdrawal managed with phenobarbital

The fact that phenobarbital, a barbiturate that enhances GABA activity, was used to manage the withdrawal aligns with kava’s GABAergic mechanism. Opioid withdrawal looks different clinically and responds to different medications. So even when kava dependence does occur, the withdrawal pattern points to GABA-system adaptations rather than anything involving opioid receptors.

For context, the profile is more analogous to what you might see with chronic heavy use of other GABA-active substances like alcohol or benzodiazepines. That doesn’t make it harmless, but it puts it in a different pharmacological category from opioid dependence.

Kava and Pain Relief Without Opioids

One reason the opioid question keeps coming up is that kava does have genuine analgesic properties. Pacific Islander cultures have used it for centuries to manage pain, and the science supports the idea that it can reduce pain sensitivity. The mechanism, as the naloxone experiment showed, has nothing to do with opioid receptors. Instead, the pain relief likely comes from multiple converging actions.

Recent research has zeroed in on yangonin’s CB1 receptor activity as one piece of this puzzle. When yangonin was injected into the spinal canal of experimental animals, it produced a strong pain-reducing effect and also reversed inflammatory hypersensitivity. Critically, these effects were completely blocked by a CB1 receptor antagonist, confirming the pain relief was running through the cannabinoid system, not the opioid one.

10PubMed. Yangonin, one of the kavalactones isolated from Piper methysticum G. Forst, acts through cannabinoid 1 (CB(1)) receptors to induce an intrathecal anti-hyperalgesia

The GABA enhancement and sodium channel blockade add further pain-dampening effects. Together, these pathways can produce meaningful analgesia without engaging opioid receptors at all. This is pharmacologically interesting because it suggests kava achieves a superficially similar endpoint through entirely different brain machinery.

Drug Interactions Worth Knowing About

Even though kava isn’t an opioid, combining it with opioid painkillers is risky. Kava’s sedating effects can add to the central nervous system depression caused by opioids, increasing the risk of excessive drowsiness, respiratory depression, and impaired coordination.

11PubMed. Herbal medication: potential for adverse interactions with analgesic drugs

The same caution applies to benzodiazepines, alcohol, and other sedatives. Two substances that both enhance GABA signaling can compound each other’s effects in unpredictable ways.

Beyond sedation stacking, kavalactones are potent inhibitors of several liver enzymes in the CYP450 family, including CYP3A4, CYP2C9, CYP1A2, and CYP2C19.

12PubMed. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.)

CYP3A4 alone is responsible for metabolizing a large share of all prescription drugs. If kava slows down these enzymes, medications that rely on them for breakdown can accumulate to higher levels in the blood than expected, potentially causing side effects or toxicity. This is a practical concern for anyone taking prescription medications regularly.

Interestingly, research on kavain’s own pharmacokinetics showed that co-administration with a full kava extract tripled the amount of kavain circulating in the blood compared to taking kavain alone. This suggests that kavalactones inhibit each other’s metabolism as well, meaning the whole-plant extract behaves differently in the body than any individual compound would.

13PubMed Central. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro

Liver Safety and Preparation Methods

Kava’s other major safety concern is liver toxicity. Several countries, including Germany, temporarily banned kava products in the early 2000s after case reports of severe liver damage. The picture has become more nuanced since then. Research has found that flavokawains A and B, which are chalcone compounds present in kava rather than kavalactones, can worsen liver damage when combined with acetaminophen, while the kavalactone dihydromethysticin did not show this effect.

14PubMed Central. Flavokawains a and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice

Kava’s ability to alter CYP450 enzyme expression may also contribute to drug-herb interactions that stress the liver.

15Journal of Medical Case Reports and Case Series. Kava Induced Hepatotoxicity In Sacramento County

How kava is prepared turns out to matter significantly. A detailed comparison of commercial kava extracts made with organic solvents like acetone, ethanol, or methanol versus traditional water-based preparations found that the commercial products contained different ratios of kavalactones and were substantially more potent at inhibiting liver enzymes.

16PubMed. Composition and biological activity of traditional and commercial kava extracts

Traditional Pacific Island preparation uses water, which extracts a different chemical profile than the solvents used in supplement manufacturing. The traditional aqueous preparation may carry a lower risk of liver-related side effects precisely because it pulls out fewer of the problematic non-kavalactone compounds like flavokawains.

Extraction technique also affects yield. Subcritical water extraction can recover kavalactone levels comparable to overnight sonication with acetone or methanol, and far more than simple boiling at atmospheric pressure.

17PubMed. Comparison of subcritical water and organic solvents for extracting kava lactones from kava root

The practical takeaway is that the form in which you consume kava matters. A supplement capsule made with an ethanol extract is chemically different from a bowl of kava prepared the traditional way with water and straining, even if both come from the same plant.

Does Kava Actually Work for Anxiety?

The evidence here is genuinely mixed. A Cochrane systematic review pooling data from multiple trials found a small but statistically significant reduction in anxiety scores with kava extract compared to placebo.

18PubMed Central. Kava extract versus placebo for treating anxiety

However, a later and larger 16-week trial with 171 participants found no significant difference between kava and placebo for generalized anxiety disorder, with the placebo group actually showing slightly higher remission rates.

19PubMed. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study

This doesn’t necessarily mean kava does nothing for anxiety, but it does suggest the effect, if real, is modest and may depend on factors like the specific kava preparation, dose, duration, and patient population. The earlier positive trials tended to be shorter and smaller. Longer, more rigorous studies have been less encouraging. Anyone considering kava specifically as an anxiety treatment should be aware that the clinical evidence is weaker than the traditional reputation suggests.

Noble, Two-Day, and Wild Varieties

Not all kava is the same plant in any functional sense. In Vanuatu, where kava cultivation has the longest history, varieties are classified into three groups based on their effects. “Noble” varieties are considered safe for daily drinking and are rich in kavain. “Two-day” varieties and wild Piper wichmanii are lower in kavain and higher in dihydrokavain and dihydromethysticin. These non-noble types are associated with nausea and are traditionally considered unsuitable for regular consumption. Noble varieties can be distinguished by their higher kavain-to-total-kavalactone ratio and lower flavokawain content.

This classification matters because the kava supplements and extracts sold outside the Pacific Islands do not always specify which variety was used. A product made from a non-noble cultivar could have a very different chemical profile and side-effect risk than one made from a noble variety. The flavokawain content that has been linked to liver toxicity is higher in non-noble and wild varieties. When someone buys a “kava” product and has a bad experience, the variety and preparation method could be as important as the dose.

How to Protect Yourself From Adulterated Products

Given the documented cases of kava products containing unlabeled kratom alkaloids or other opioid-active botanicals, the question of product quality is more than academic. A product that contains mitragynine without listing it on the label is not just mislabeled; it puts users at risk for opioid dependence from something they believe is opioid-free.

If you use kava, a few practical considerations are worth keeping in mind:

  • Source matters: Traditional kava root from known suppliers in the Pacific Islands, ideally noble varieties, has a different risk profile than anonymous herbal blends marketed as “kava” in gas stations or online.
  • Preparation matters: Water-based preparations are closer to the traditional method and appear to carry lower liver risk than solvent-extracted supplements.
  • Polyherbal blends are risky: Products that list multiple botanicals alongside kava, especially akuamma or unlisted ingredients, are where the adulteration cases have concentrated.
  • Watch for opioid-like effects: If a kava product produces pronounced drowsiness, pupil constriction, or withdrawal symptoms that feel like the flu, those are red flags that it may contain something other than kava.

Kavalactone-specific lab testing exists but is not routinely available to consumers. The supplement industry in the United States operates under less regulatory scrutiny than pharmaceuticals, which means the label on a kava product is sometimes an aspiration rather than a guarantee. Third-party testing certifications, when available, offer some additional confidence that what’s in the bottle matches what’s on the label.

Kava’s MAO-B Inhibition and Dopamine

One aspect of kava’s pharmacology that deserves its own attention is the MAO-B inhibition, because it connects kava to a category of drugs people may not expect. MAO-B inhibitors are used clinically to treat Parkinson’s disease, where they help preserve dopamine levels in areas of the brain involved in movement. Kava is not being proposed as a Parkinson’s treatment, but the mechanism has interesting implications.

Yangonin is the most potent kavalactone MAO inhibitor, with strong activity against both MAO-A and MAO-B.

20PubMed. Monoamine Oxidase Inhibition by Kavalactones from Kava (Piper Methysticum)

Kavain also inhibits MAO-B. In animal studies, kava extract at relatively low doses inhibited MAO-B activity in the brain cortex and in the region containing the substantia nigra, a dopamine-rich area.

21PubMed Central. Ex vivo and in vitro inhibitory potential of Kava extract on monoamine oxidase B activity in mice

MAO inhibition could explain why kava produces a different quality of relaxation than, say, alcohol or a benzodiazepine. Both of those are purely GABAergic, producing sedation without much mood lift. Kava’s simultaneous GABA enhancement and dopamine preservation could account for the alert, sociable calm that traditional kava drinkers describe, a state that doesn’t map onto the sedative-only experience of other anxiolytics. It is also a reminder that combining kava with other substances that affect serotonin or dopamine, including certain antidepressants, could carry risks that haven’t been well studied.